Table 11.
Antiviral activity of inhibitor 25 against clinical HIV‐1 isolates in PBMC cells.
|
Virus[a] |
IC50 values [nm] |
||||
|---|---|---|---|---|---|
|
SQV |
IDV |
APV |
DRV |
25 |
|
|
HIV‐1ERS104pre (wild‐type: X4) |
12 |
26 |
33 |
3.5 |
29 |
|
HIV‐1MDR/MM (R5) |
190 (16) |
>1000 (>38) |
300 (9) |
17 (5) |
150 (5) |
|
HIV‐1MDR/JSL (R5) |
330 (28) |
>1000 (>38) |
430 (13) |
26 (7) |
550 (19) |
|
HIV‐1MDR/C (X4) |
36 (3) |
>1000 (>38) |
230 (7) |
7 (2) |
300 (10) |
|
HIV‐1MDR/G (X4) |
29 (2) |
290 (11) |
340 (10) |
7 (2) |
340 (12) |
|
HIV‐1MDR/A (X4) |
81 (7) |
>1000 (>38) |
100 (3) |
3 (1) |
21 (1) |
[a] Amino acid substitutions identified in the protease‐encoding region compared to the consensus type B sequence cited from the Los Alamos database, see reference 129 for details.